Promising Results from Study but More Work Needed for Healthcare Equity in Kenya

By Staff Writer

August 31, 2023

The African Health Markets for Equity (AHME) program has shown encouraging results in improving access to and quality of private health clinics in Kenya, according to a recent study. The research, a cluster randomised controlled trial, aimed to determine if the combination of social health insurance and management training could enhance healthcare services in the country.

The study revealed that AHME significantly impacted clinics, with the treatment group reporting a 26.0% increase in total clients and a 51.3% increase in National Hospital Insurance Fund (NHIF) clients. AHME also increased the likelihood of individuals having any form of health insurance, whether public or private.

However, the study did not find that AHME was successful in promoting pro-poor private healthcare. Poor households were significantly less likely to have health insurance, and there was no additional effect of AHME for this group. The study also found that AHME did not improve the quality of care for poor clients.

AHME focused on social health insurance as a mechanism for low-income households to receive high-quality healthcare at private or public clinics. The intervention encouraged and assisted private clinics to register under the NHIF scheme. This resulted in large effects on clinic registration and significant increases in the number of clients with public insurance served.

Despite these positive outcomes, more work is needed to improve insurance enrollment for poorer households. The study suggests that future research should focus on understanding the mechanisms through which increased clinic NHIF registration might increase demand-side insurance enrollment.

Reference url

Recent Posts

FDA warning Aspen Pharmacare
   

FDA Warning Aspen Pharmacare: Evaluating Compliance Violations and Their Impact

🚨 Is your pharmaceutical brand prepared for FDA scrutiny?

Aspen Pharmacare Holdings recently faced a serious FDA warning highlighting significant violations in its manufacturing practices. These issues not only jeopardize product quality but also threaten access to vital medicines for patients.

Explore the implications of regulatory compliance on brand reputation and global supply in the full article!

#SyenzaNews #pharmaceuticals #regulatoryaffairs #MarketAccess

pharmaceutical innovation 2025
      

Pharmaceutical Innovation and Market Access: Insights from Fast Company’s 2025 Top List

💊 Explore how top pharma companies are driving change in 2025! This article breaks down key innovations and smart access strategies from Fast Company’s most impactful list—giving you actionable insights into pharma innovation and market access 2025. 🚀

#SyenzaNews #pharmaceuticals #AIinHealthcare #innovation

global partnerships SCD
    

Global Partnerships SCD in Africa

🌍 How can global partnerships transform care for sickle cell disease in Africa?

In the latest article, we explore the significant strides made by the SickleInAfrica consortium, which highlights the power of collaboration in enhancing SCD management through comprehensive patient registries, clinical guidelines, and innovative research. These efforts not only improve health outcomes but also pave the way for sustainable solutions across the continent.

Dive deeper into this crucial conversation and discover how international forums are shaping the future of SCD care!

#SyenzaNews #globalhealth #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.